Immunohistochemistry validation is much more than simply 20 positives and 20 
negative cases, though this will allow you to meet most accreditation 
requirements.

Validation is a multi step process:
1.      Optimisation: following a thorough literature review (what should and 
should not stain, clones used (any difference), recommended assay conditions 
(eg antigen retrieval type), choose an appropriate control to confirm staining 
conditions and perform an optimum titre.
2.      Validation: based on the literature review, choose appropriate known 
(or expected) positives and negative cases that the pathologists would 
entertain in the differential diagnosis that should be negative.

Take Prostate Specific Antigen as an example, include known prostatic 
carcinomas with a mix of well, moderately and poorly differentiated prostatic 
carcinomas and include negative tumours that should not express PSA (eg 
melanomas, lymphomas, colonic and lung carcinomas).

This is a scientific approach that inspires confidence in the usefulness of the 
test.

3.      Another task that we find extremely useful is on-going Verification, 
where we compare staining results with final diagnosis of cases immunostained 
for the marker.

Food for thought?

Regards 
Tony Henwood JP, MSc, BAppSc, GradDipSysAnalys, CT(ASC), FFSc(RCPA) 
Principal Scientist, the Children's Hospital at Westmead
Adjunct Fellow, School of Medicine, University of Western Sydney 
Tel: 612 9845 3306 
Fax: 612 9845 3318 
Pathology Department
the children's hospital at westmead
Cnr Hawkesbury Road and Hainsworth Street, Westmead
Locked Bag 4001, Westmead NSW 2145, AUSTRALIA 

-----Original Message-----
From: Nancy Schmitt via Histonet [mailto:histonet@lists.utsouthwestern.edu] 
Sent: Wednesday, 25 October 2017 4:16 AM
To: 'histonet@lists.utsouthwestern.edu'
Subject: [Histonet] validation

Good Day!
When performing validation on IHC, we use 20 positives and 20 negative cases.

When testing for negative, can the normal tissue surrounding the tumor be 
counted as negative?

Does the negative tissue need to be tumor that is negative for the AB or just 
normal tissue?

Thank you for your consideration,

Nancy
Dubuque, IA
Ph. 563-589-9810



NOTICE: This email may contain legally privileged information. The information 
is for the use of only the intended recipient(s) even if addressed incorrectly. 
If you are not the intended recipient, please notify the sender that you have 
received it in error and then delete it along with any attachments. Thank you.




NOTICE: This email may contain legally privileged information. The information 
is for the use of only the intended recipient(s) even if addressed incorrectly. 
If you are not the intended recipient, please notify the sender that you have 
received it in error and then delete it along with any attachments. Thank you.


_______________________________________________
Histonet mailing list
Histonet@lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet

This message is intended for the addressee named and may contain confidential 
information. If you are not the intended recipient, please delete it and notify 
the sender.

Views expressed in this message are those of the individual sender, and are not 
necessarily the views of NSW Health or any of its entities.


_______________________________________________
Histonet mailing list
Histonet@lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet

Reply via email to